Exparel is a long-acting bupivacaine which combines product delivery technology, DepoFoam and is an anesthetic/analgesic.
The data has been pooled from five active-control, double-blind, randomized, multicenter, parallel-group trials comprising over 700 patients.
The study demonstrated that Exparel resulted in longer time to first opioid use (TTFO), a reduced overall consumption of opioids, fewer opioid-related adverse events (ORAEs) and better pain control compared to bupivacaine HCl.